• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.转移性结直肠癌化疗使用的纵向模式。
J Oncol Pract. 2009 Sep;5(5):228-33. doi: 10.1200/JOP.091010.
2
Advances in chemotherapy against advanced or metastatic colorectal cancer.晚期或转移性结直肠癌化疗的进展
Digestion. 2008;77 Suppl 1:13-22. doi: 10.1159/000111483. Epub 2008 Jan 18.
3
Management of advanced colorectal cancer, Part 1.晚期结直肠癌的治疗（一）
Am J Health Syst Pharm. 2013 Mar 1;70(5):395-406. doi: 10.2146/ajhp110532.
4
Management of advanced colorectal cancer, Part 2.晚期结直肠癌的治疗，第二部分。
Am J Health Syst Pharm. 2013 Mar 15;70(6):491-506. doi: 10.2146/ajhp110532b.
5
Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.老年患者结直肠癌的管理：关注化疗费用
Drugs Aging. 2004;21(2):113-33. doi: 10.2165/00002512-200421020-00004.
6
Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration.晚期或转移性结直肠癌的姑息化疗。结直肠癌荟萃分析协作组。
Cochrane Database Syst Rev. 2000;2000(2):CD001545. doi: 10.1002/14651858.CD001545.
7
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.西妥昔单抗（技术评估报告第176号综述）和帕尼单抗（技术评估报告第240号部分综述）用于既往未治疗的转移性结直肠癌的临床疗效和成本效果：一项系统评价与经济学评估
Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380.
8
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.晚期结直肠癌治疗方案的生存和疾病进展获益：一项荟萃分析。
Lancet Oncol. 2007 Oct;8(10):898-911. doi: 10.1016/S1470-2045(07)70281-4. Epub 2007 Sep 20.
9
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.老年常见转移性恶性肿瘤患者的姑息化疗：希腊合作肿瘤学组关于管理、结局及临床获益预测因素的登记分析
Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1.
10
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.接受基于5-氟尿嘧啶方案治疗的晚期结直肠癌患者短期生存及化疗进展的预测因素
Am J Clin Oncol. 2002 Apr;25(2):140-8. doi: 10.1097/00000421-200204000-00008.

引用本文的文献

1
Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.美国转移性结直肠癌白种人和黑种人医疗保险患者中生物制剂的比较疗效。
JAMA Netw Open. 2021 Dec 1;4(12):e2136378. doi: 10.1001/jamanetworkopen.2021.36378.
2
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.系统评价和网络荟萃分析转移性结直肠癌的三线治疗方法。
J Cancer Res Clin Oncol. 2020 Oct;146(10):2575-2587. doi: 10.1007/s00432-020-03315-6. Epub 2020 Jul 27.
3
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.中国转移性结直肠癌患者的疾病特征和治疗模式：一项使用中国病历的回顾性研究。
BMC Cancer. 2020 Feb 18;20(1):131. doi: 10.1186/s12885-020-6557-5.
4
A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.一项回顾性观察研究，旨在估计加拿大转移性结直肠癌系统治疗线间患者的流失情况。
Curr Oncol. 2019 Dec;26(6):e748-e754. doi: 10.3747/co.26.4861. Epub 2019 Dec 1.
5
Cost-effectiveness analysis of selective first-line use of biologics for unresectable wild-type left-sided metastatic colorectal cancer.不可切除的野生型左侧转移性结直肠癌一线选择性使用生物制剂的成本效益分析。
Curr Oncol. 2019 Oct;26(5):e597-e609. doi: 10.3747/co.26.4843. Epub 2019 Oct 1.
6
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.美国转移性胰腺癌患者队列中的化疗使用模式。
Oncologist. 2017 Aug;22(8):925-933. doi: 10.1634/theoncologist.2016-0447. Epub 2017 May 5.
7
Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study.卡培他滨单药治疗转移性结直肠癌的耐受性：一项真实世界研究。
Drugs R D. 2017 Mar;17(1):117-124. doi: 10.1007/s40268-016-0154-8.
8
Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.老年（年龄>65岁）转移性结肠癌医疗保险患者各治疗线生物制剂使用模式。
Oncologist. 2016 Jun;21(6):676-83. doi: 10.1634/theoncologist.2015-0199. Epub 2016 Apr 28.
9
Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study.结直肠癌与乳腺癌、肺癌或前列腺癌医学肿瘤门诊患者的神经病变症状及其危险因素：一项前瞻性多中心研究的结果
J Pain Symptom Manage. 2015 Jun;49(6):1016-24. doi: 10.1016/j.jpainsymman.2014.11.300. Epub 2015 Jan 14.
10
Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.肿瘤学家对关于表皮生长因子受体抑制剂在结直肠癌中应用的新数据的反应。
J Oncol Pract. 2014 Sep;10(5):308-14. doi: 10.1200/JOP.2014.001439. Epub 2014 Jul 22.

本文引用的文献

1
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.贝伐单抗联合奥沙利铂为基础的化疗作为转移性结直肠癌的一线治疗：一项随机III期研究。
J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.
2
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.伊立替康联合持续静脉输注、大剂量推注或口服氟嘧啶用于转移性结直肠癌一线治疗的随机对照试验：BICC-C研究结果
J Clin Oncol. 2007 Oct 20;25(30):4779-86. doi: 10.1200/JCO.2007.11.3357.
3
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.伊立替康联合氟尿嘧啶及亚叶酸钙作为Ⅲ期结肠癌辅助治疗并不优于单独使用氟尿嘧啶及亚叶酸钙：癌症和白血病B组89803研究结果
J Clin Oncol. 2007 Aug 10;25(23):3456-61. doi: 10.1200/JCO.2007.11.2144.
4
The continuum of care: a paradigm for the management of metastatic colorectal cancer.连续护理：转移性结直肠癌管理的范例
Oncologist. 2007 Jan;12(1):38-50. doi: 10.1634/theoncologist.12-1-38.
5
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.奥沙利铂联合氟尿嘧啶/亚叶酸钙每两个月给药一次用于老年结直肠癌患者的安全性和疗效的汇总分析。
J Clin Oncol. 2006 Sep 1;24(25):4085-91. doi: 10.1200/JCO.2006.06.9039.
6
Analysis of treatment practices for elderly cancer patients in Ontario, Canada.加拿大安大略省老年癌症患者治疗实践分析
J Clin Oncol. 2005 Jun 1;23(16):3802-10. doi: 10.1200/JCO.2005.06.742.
7
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.奥沙利铂、氟尿嘧啶和亚叶酸作为结肠癌的辅助治疗。
N Engl J Med. 2004 Jun 3;350(23):2343-51. doi: 10.1056/NEJMoa032709.
8
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.一项针对既往未接受治疗的转移性结直肠癌患者，比较氟尿嘧啶联合亚叶酸、伊立替康及奥沙利铂不同组合的随机对照试验。
J Clin Oncol. 2004 Jan 1;22(1):23-30. doi: 10.1200/JCO.2004.09.046. Epub 2003 Dec 9.
9
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.晚期结直肠癌中FOLFIRI序贯FOLFOX6或相反顺序：一项GERCOR随机研究
J Clin Oncol. 2004 Jan 15;22(2):229-37. doi: 10.1200/JCO.2004.05.113. Epub 2003 Dec 2.
10
Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort.基于人群队列的辅助化疗和放疗在结直肠癌中的应用。
J Clin Oncol. 2003 Apr 1;21(7):1293-300. doi: 10.1200/JCO.2003.06.178.

转移性结直肠癌化疗使用的纵向模式。

Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.

机构信息

Cancer Center Biostatistics; Division of Medical Oncology, Department of Medicine; and Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC.

出版信息

J Oncol Pract. 2009 Sep;5(5):228-33. doi: 10.1200/JOP.091010.

DOI:10.1200/JOP.091010
PMID:20856733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2790671/
Abstract

Multiple agents and combination therapies available to patients with advanced colorectal cancer have significantly improved survival and provided an opportunity for individualization of care, allowing clinicians and patients to prioritize risks and benefits of comparable regimens.

摘要

对于晚期结直肠癌患者，多种药物和联合治疗方案显著提高了生存率，并为个体化治疗提供了机会，使临床医生和患者能够权衡可比治疗方案的风险和获益。